Link-Asia International Medtech Group Ltd. (1143) AI Stock Analysis

• Market Cap: HK$86.35M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: -25.16%
• EPS Growth: -160.31%
• Country: HK
• Employees: 835
• Sector: Technology
• Sector Strength: 88
• Industry: Consumer Electronics
• EPS (TTM): -0.07
• Shares Outstanding: 224,289,180
• 10 Day Avg. Volume: 1,292,540
• 30 Day Avg. Volume: 1,091,788
• PEG Ratio: 0.29
• Price to Book (P/B): 0.13
• Price to Sales (P/S): 0.14
• P/FCF Ratio: -0.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: HK$0.50 ▲(31.58% Upside)

Link-Asia International Medtech Group Ltd. has a mixed outlook. The most significant factor is its financial performance, which shows stability in equity but challenges in revenue and cash flow. Technical analysis suggests a positive short-term trend, but valuation concerns due to negative profitability weigh heavily on the overall score.

Positive Factors

Stable Equity Position

A stable equity position with a balanced capital structure indicates a solid financial foundation, supporting long-term growth and resilience against market fluctuations.

Positive EBIT Margin

Achieving a positive EBIT margin reflects improved operational efficiency, which can enhance profitability and provide a buffer against economic downturns.

Improved Free Cash Flow

Improved free cash flow enhances the company's ability to invest in growth opportunities, pay down debt, and return capital to shareholders, supporting long-term financial health.

Negative Factors

Declining Revenue Trend

A declining revenue trend indicates challenges in maintaining market share and demand for products, which can hinder long-term growth and profitability.

Inconsistent Cash Flow Management

Inconsistent cash flow management can strain liquidity, limiting the company's ability to invest in growth initiatives and manage financial obligations effectively.

Volatile Net Profit Margins

Volatile net profit margins suggest challenges in cost control and pricing power, which can affect the company's ability to sustain profitability over the long term.

Link-Asia International Medtech Group Ltd. Business Overview & Revenue Model

Company Description

Link-Asia International MedTech Group Limited, an investment holding company, provides electronic manufacturing services (EMS) for the telecommunications, security, car electronics, home appliances, other consumer, and industrial electronic products. The company operates through four segments: EMS, Distribution of Communications Products, Securities and Other Assets Investment, and Real Estate Supply Chain Services. It is also involved in the trade of personal care products, business telephone systems, and telecommunication products; manufacture and sale of telecommunications and other products, and consumable electronic products; sale of audio equipment; and provision of consultancy services, as well as pre-pregnancy care and assisted reproductive services. In addition, the company offers equity investment and property agency services; and real estate advisory and purchase services. It operates in the People's Republic of China, the United States, Switzerland, France, Poland, the United Kingdom, Belgium, Russia, Thailand, Malaysia, Brazil, and internationally. The company was formerly known as Link-Asia International Co. Ltd. and changed its name to Link-Asia International MedTech Group Limited in December 2020. Link-Asia International MedTech Group Limited was founded in 1992 and is headquartered in Tsim Sha Tsui, Hong Kong.

How the Company Makes Money

Link-Asia International Medtech Group Ltd. generates revenue through multiple streams, primarily by selling its medical devices and technologies to healthcare providers, hospitals, and clinics. The company's revenue model is centered around direct sales, distribution agreements, and partnerships with healthcare institutions. Additionally, Link-Asia may engage in research and development collaborations, potentially leading to licensing agreements for new technologies. The company's financial performance can also be influenced by government contracts or grants, industry partnerships, and the overall demand for medical technology solutions in the markets it serves.

Link-Asia International Medtech Group Ltd. Financial Statement Overview

Summary

Link-Asia International Medtech Group Ltd. shows a mixed financial profile. While the balance sheet is stable with a moderate debt-to-equity ratio, the company faces challenges with declining revenues and inconsistent cash flow management. The positive EBIT margin in 2024 is a positive sign, but overall profitability and liquidity concerns remain.

Income Statement

Link-Asia International Medtech Group Ltd. has shown mixed results over recent years. The company experienced declining revenues with a negative growth trend from 2019 to 2024, particularly from 2021 to 2024. While gross profit margins remained relatively stable, net profit margins were volatile, indicating potential profitability issues. The positive EBIT margin in 2024 is a welcome improvement, although historical EBIT margins were negative.

Balance Sheet

The company's balance sheet reveals a stable equity position with a moderate debt-to-equity ratio, indicating a balanced capital structure. The equity ratio has improved over time, suggesting a strengthening financial foundation. However, the fluctuating total debt and liabilities pose potential risks to financial stability.

Cash Flow

Cash flow analysis indicates inconsistent cash flow management. Operating cash flow was negative in several years, impacting free cash flow generation. Though there was a significant improvement in free cash flow in 2022, the lack of consistent positive cash flow raises concerns about long-term liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	402.85M	479.32M	502.00M	529.25M	675.52M	595.02M
Gross Profit	90.89M	123.60M	136.87M	101.40M	144.89M	154.71M
EBITDA	14.14M	4.78M	40.49M	-14.06M	-4.54M	-116.52M
Net Income	-4.33M	8.04M	5.26M	-54.04M	-46.40M	-173.05M
Balance Sheet
Total Assets	875.18M	880.14M	776.42M	659.23M	677.98M	657.40M
Cash, Cash Equivalents and Short-Term Investments	331.35M	312.05M	271.57M	252.21M	146.80M	167.66M
Total Debt	94.77M	86.60M	26.75M	51.08M	61.20M	70.19M
Total Liabilities	343.00M	343.25M	287.69M	297.22M	311.98M	361.47M
Stockholders Equity	532.05M	536.53M	486.66M	359.86M	365.88M	295.46M
Cash Flow
Free Cash Flow	-47.91M	-75.67M	-132.09M	99.60M	-122.55M	-45.85M
Operating Cash Flow	-43.60M	-73.19M	-129.29M	107.55M	-100.45M	-15.04M
Investing Cash Flow	15.74M	49.83M	48.86M	2.13M	3.31M	-96.19M
Financing Cash Flow	55.49M	66.31M	101.84M	4.68M	74.19M	35.17M

Link-Asia International Medtech Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1143, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.41, and above the 200-day MA of 0.37, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.11 is Neutral, neither overbought nor oversold. The STOCH value of 33.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1143.

Link-Asia International Medtech Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
1143	51 Neutral	HK$86.35M	-19.95	-0.82%	―	-25.16%	-160.31%
0110	47 Neutral	HK$56.80M	-3.35	-216.50%	―	-35.77%	-1.06%
8147	47 Neutral	HK$186.51M	36.29	―	―	21.86%	―
0328	41 Neutral	HK$151.22M	-1.36	―	―	-0.76%	93.44%

Link-Asia International Medtech Group Ltd. Corporate Events

Link-Asia Proposes Scheme Mandate Limit Refreshment

Link-Asia International Medtech Group Ltd. has announced a proposed refreshment of its Scheme Mandate Limit under the 2023 Share Option Scheme. This move is intended to provide the company with greater flexibility to motivate and reward participants for their contributions to the company. The refreshment is subject to shareholder approval at the upcoming EGM and would increase the maximum number of shares that can be issued under the scheme to 10% of the issued shares as of the EGM date. The company emphasizes that this refreshment is in the best interests of both the company and its shareholders.

China Energy Storage Completes Strategic Acquisition

China Energy Storage Technology Development Limited has completed the acquisition of the entire equity interest in a target company, making it a wholly-owned subsidiary. The acquisition, finalized on September 18, 2025, involved a consideration adjustment based on the net asset value, resulting in a final payment of HK$21,124,996. This strategic move will see the financial results of the acquired company consolidated into the group’s financial statements, potentially strengthening its market position in the energy storage sector.

Link-Asia International Medtech Group Ltd. Announces Strategic Acquisition

Link-Asia International Medtech Group Ltd., a company incorporated in the Cayman Islands, has announced a significant acquisition. The company has entered into a Sale and Purchase Agreement to acquire the entire equity interest in a target company for HK$20,800,000, subject to adjustments. This acquisition, which will make the target company an indirect wholly-owned subsidiary, is classified as a discloseable and connected transaction under the Hong Kong Listing Rules. The transaction has been approved by the Board and deemed fair and reasonable by the independent non-executive Directors, thus exempting it from certain regulatory requirements.